Core Viewpoint - vTv Therapeutics Inc. has received a Notice of Allowance from the USPTO for a patent application related to cadisegliatin, which strengthens the protection of this potential first-in-class oral adjunctive therapy for type 1 diabetes [1][2] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases [4] - The company's lead asset, cadisegliatin, is currently in a Phase 3 trial and has been granted Breakthrough Therapy designation by the FDA [2][4] Product Details - Cadisegliatin (TTP399) is a liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes [2] - In non-clinical studies, cadisegliatin has shown the ability to increase glucokinase activity independently from insulin, which may improve glycemic control [2] Patent Information - The patent term for the compositions of matter related to cadisegliatin runs through 2041, providing long-term protection for the innovation [1][2]

Core Insights - vTv Therapeutics Inc. has initiated the CATT1 Phase 3 trial for cadisegliatin, an oral glucokinase activator for type 1 diabetes, with topline results expected in the second half of 2026 [1][2] - The trial aims to enroll approximately 150 participants across 25 sites in the U.S., evaluating the efficacy and safety of cadisegliatin compared to placebo [2][4] - Cadisegliatin has received Breakthrough Therapy designation from the FDA and has shown good tolerability in over 500 subjects [1][2] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for diabetes and other chronic diseases [6] - The company's lead program, cadisegliatin, is being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes [6] Industry Context - There is a significant unmet need for therapeutic advances in type 1 diabetes, as current medical devices have not been complemented by effective oral adjunct therapies [2][3] - The introduction of glucokinase activators like cadisegliatin could potentially improve glycemic control while reducing the risks of hypoglycemia and diabetic ketoacidosis [3][4]